Reagent kit for the analysis of human serum or blood plasma for the presence of specific class G immunoglobulins to the SARS-CoV-2 virus nucleocapsid by enzyme-linked immunosorbent assay (ELISA anti-SARS-CoV-2 IgG reagent kit as per TU 21.20.23-356-78095326-2021, Series 07 1. SARS-CoV-2 IgG Tablet - 2 pcs. 2. K+ SARS-CoV-2 IgG, 4.0 ml - 1 vial. 3. K-SARS-CoV-2 IgG, 4.0 ml - 1 vial. 4. 200x anti-IgG conjugate concentrate, 0.3ml - 1 vial. 5. 10-x solution for dilution and washing, 40.0 ml - 3 vials. 6. TMB, 14.0 ml - 2 vials. 7. Stop reagent, 10.0 ml - 1 vial. 8. Instructions for use - 1 pc. 9. Quality passport - 1 pc. - Roszdravnadzor Registration РЗН 2022/16468
Access comprehensive regulatory information for Reagent kit for the analysis of human serum or blood plasma for the presence of specific class G immunoglobulins to the SARS-CoV-2 virus nucleocapsid by enzyme-linked immunosorbent assay (ELISA anti-SARS-CoV-2 IgG reagent kit as per TU 21.20.23-356-78095326-2021, Series 07 1. SARS-CoV-2 IgG Tablet - 2 pcs. 2. K+ SARS-CoV-2 IgG, 4.0 ml - 1 vial. 3. K-SARS-CoV-2 IgG, 4.0 ml - 1 vial. 4. 200x anti-IgG conjugate concentrate, 0.3ml - 1 vial. 5. 10-x solution for dilution and washing, 40.0 ml - 3 vials. 6. TMB, 14.0 ml - 2 vials. 7. Stop reagent, 10.0 ml - 1 vial. 8. Instructions for use - 1 pc. 9. Quality passport - 1 pc. in the Russia medical device market through Pure Global AI's free database. This Class 2b medical device is registered under Roszdravnadzor registration number РЗН 2022/16468 and manufactured by State Research Center for Applied Microbiology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Welfare. The device was registered on February 01, 2022.
This page provides complete registration details including device type, manufacturer information, country of origin (Russia), and regulatory compliance data from the official Russia Roszdravnadzor medical device database. Pure Global AI offers free access to Russia's complete medical device registry, helping global MedTech companies navigate Roszdravnadzor regulations efficiently.

